Sanofi has signed a $1.2bn licensing agreement with Novavax to co-commercialise its stand-alone adjuvanted Covid-19 vaccine. Starting in 2025, the drugmaker will co-commercialise the vaccine ...

Novavax, also I know is on your radar. We're looking at shares up just about 9% earnings helping to maybe alleviate some of the concern that we've seen plaguing the stock. 00:09 Speaker B ...

Novavax reported $88 million in revenues in the fourth quarter, compared to $291 million the year prior, and $682 million for the full year 2024, compared to $984 million the previous year.